Hapoalim Securities initiates coverage on Protalix BioTherapeutics (NYSE Amex: PLX) with an Outperform rating, price target $10.

Hapoalim analyst says, "The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE